MedTrace Logo

Bone Resorption, Osteoclastogenesis and Adalimumab

NCT02035800 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2018-05-08

No results posted yet for this study

Summary

Broca II is the prolongation of the original study name BROCA. In BROCA study, only 25 patients participated and it was not enough to concluded clearly our hypothesis.

Conditions

Interventions

DRUG

Adalimumab

Patient will received medication as standard of care

Sponsors & Collaborators

  • AbbVie

    collaborator INDUSTRY

  • Université de Sherbrooke

    lead OTHER

Principal Investigators

  • Artur Ferandnes · Centre de recherche Étienne Le-Bel at Centre hospitalier universitaire de Sherbrooke

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2018-12-31
Completion
2019-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02035800 on ClinicalTrials.gov